The Aptima Virology portfolio delivers on the Hologic promise of innovation through life-changing viral testing for viruses that impact patients across the globe. Aptima Virology assays for HIV-1, HCV and HBV deliver reliable quantitation to aid in the management of these challenging viruses.
As treatment options continue to evolve in the viral space, Hologic has answered the call for highly sensitive nucleic acid amplification tests (NAATs) with Aptima Virology assays on the fully automated Panther system. Our Aptima Virology portfolio may be run in conjunction with the Aptima STI (sexually transmitted infections) portfolio and Aptima HPV assays. This consolidated menu streamlines workflow providing a solution to the challenges faced by today’s molecular lab.
The Aptima Virology portfolio has a legacy of innovation and leadership in the viral space in the United States and globally. This legacy began with the release of qualitative NAATs for HIV-1 and HCV in the 1990s. Recent menu additions include viral load testing for HIV-1, HCV and HBV.
The Aptima viral load assays on the Panther system deliver strong assay performance, industry-leading sensitivity, broad dynamic range and flexibility in sample requirements demonstrated through substantial data and designed with users in mind.
One assay with multiple uses, the Aptima HIV-1 Quant Dx assay is used as an aid in the diagnosis of HIV-1 infection, and as a confirmation of HIV-1 infection, in conjunction with clinical presentation and other laboratory markers for disease prognosis in HIV-1 infected individuals. It is also used as an aid in the clinical management of antiretroviral treatment. The assay has excellent performance, so laboratorians can measure changes in the concentration of HIV-1 RNA with confidence. This assay uses NAAT precision for viral load testing.
Further expanding the hunt for viral load targets, the Aptima HCV Quant Dx assay features ultrasensitive performance across a wide linear range and all major HCV genotypes. This assay is indicated for the confirmation of active infection after a positive antibody test and to monitor patients undergoing HCV antiviral drug therapy.
The Aptima HBV Quant assay is a molecular HBV treatment management assay with dual-target design. It helps providers guide treatment management for patients with chronic HBV infection undergoing antiviral therapy. This unique design allows laboratorians to deliver results in the face of mutations.
The robust performance of the Aptima viral load assays, demonstrated through substantial data, provides confidence in ensuring excellence in the clinical management of patients. This proven performance, combined with the benefits of Panther system automation, promote flexibility and operational efficiency for viral load testing success in molecular labs across the world.
|Product Division||Laboratory Division|